CD22 and neoplasm: In a NOD/SCID/ɣ (NSG) mouse CD19+/CD22+ tumor model, AUTO3 demonstrated improved efficacy over the FMC63 CAR with equivalent persistence in the bone marrow (Fig. 1d).